Armata Pharmaceuticals Secures $3.7M DoW Funding for AP-SA02 Phase 3; Shares Fall

Armata Pharmaceuticals (ARMP) said on September 23, 2026, it received an additional $3.7 million in non-dilutive funding from the U.S. Department of War to support Phase 3 development of AP-SA02 in complicated Staphylococcus aureus bacteremia (SAB). Shares declined following the announcement. The funding adds to prior government support for the bacteriophage candidate, which targets drug-resistant SAB infections. Armata did not disclose updated timelines or enrollment figures for the Phase 3 program. Investors appeared to look past the non-dilutive capital, with ARMP stock trading lower on the session. The company is a clinical-stage biotech developing phage-based therapeutics.